PREFER
Start date:Historic End date:
June 2014 Co-ordinated by:
Daiichi Sankyo Deutschland GmbH, Munich
Prefer in VTE Prevention of Thromboembolic Events – European Registry in Venous Thromboembolism
Aim
To assess the 12 month direct health care resource use and estimated costs following acute first-time (initial) or recurrent VTE
Trial Design
Multi –national, multi-centre, prospective observational disease registry
Chief Investigator
Dr Petra Laeis, Munich
Local PI
Dr. Matt Reed
Local PI
Dr Matt Reed
Director of EMERGE, Consultant, NRS Career Research Fellow & Honorary Reader in Emergency Medicine
More EMERGE Trials
Diagnostics devices play an important part in the clinical assessment of a patient’s health and treatment. The purpose of the study is the evaluation of a new diagnostic platform developed by LumiraDx. The evaluation is focused around various biomarkers useful in the emergency settings.
NOVEL Study
Collection of venous and capillary blood samples for the evaluation of new diagnostic devices for cardiovascular conditions
Early diagnosis is central to improving outcomes for patients with cancer. For cancers without specific risk factors, or with no screening programs are difficult to diagnose and patients often present with non-specific symptoms. Unfortunately this means that these patients are often diagnosed late on in the development of the disease and treatment options are reduced.
INFERENCE
ATTEST2 Trial
Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)